Fig. 4

No associations between TMB or predicted neopeptides across immune clusters. A, B Boxplots showing TMB defined as SNV per megabase (Mb) (A) or SNV + Indel per Mb (B) across immune clusters in pedNST. ANCOVA, not significant. C Boxplot showing TMB for pedHGG samples across immune clusters. Two-sided rank sum test, *p < 0.05. D Boxplot showing number of predicted strong binding peptides (defined as binding affinity ≤ 0.5) for pedNST samples across immune clusters. ANCOVA, not significant. E Boxplot showing number of predicted strong binding peptides for pedHGG samples across immune clusters. Two-sided rank sum test, *p < 0.05. F Heatmap illustrating scaled number of samples (z-score) with at least one non-synonymous SNV/Indels in genes involved in oncogenic pathways, as defined by TCGA. Barplot shows the total number of samples with alterations in each pathway. Stacked barplot shows proportion of tumour types present in samples with alterations in each pathway. Numbers in brackets indicate the number of altered genes in each pathway. G Oncoprint illustrating the distribution of somatic mutations in the top 15 most commonly altered genes in pedNST across the four immune clusters. In all boxplots, boxes show median and IQR and whiskers represent 1.5 times IQR